TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting by revealing additional data from its Phase 1 PERIO-01 clinical trial of SD-101. The study, which centers on the treatment of liver metastases from uveal melanoma, utilized the company’s proprietary Pressure-Enabled Drug Delivery (PEDD) with TriNav Infusion System in combination with systemic checkpoint inhibitors, showing a well-tolerated treatment protocol with potential systemic immunologic benefits.

TriSalus’ PERIO-01 Trial Highlights Optimal Dosing and Patient Responses

The PERIO-01 trial outcomes have been notably promising, with SD-101 showing a favorable safety profile and immunologic activity. At the optimal dose level in combination with nivolumab, patients experienced a median PFS of nearly 12 months and a disease control rate surpassing 80%. Statements from TriSalus’ Chief Medical Officer, Dr. Steven C. Katz, and Dr. Sapna Patel from MD Anderson Cancer Center, affirm the trial’s encouraging findings and the potential for the optimized dosing strategy.

TriSalus’ Study Reveals Positive Immune Response and Clinical Efficacy

Further details from the PERIO-01 study presented at SITC 2023 reveal that patients receiving the innovative SD-101 therapy via PEDD in combination with nivolumab saw positive immune responses, with increased activation and proliferation of key immune cells. The clinical efficacy was also underscored by ctDNA molecular response rates and significant disease control, even in previously treated patients.

The comprehensive data from the Phase 1 clinical trial highlight the potential of SD-101 in improving treatment for those suffering from liver and pancreatic tumors. TriSalus Life Sciences’ presentation at SITC 2023 underscores its commitment to developing therapies that address the unmet needs in the oncology space, with a focus on leveraging immunotherapy and novel delivery technologies to improve patient outcomes.

  Dr. Sapna Patel, Dr. Steven C. Katz, MD Anderson Cancer Center, SD-101, SITC 2023, TriSalus Life Sciences, uveal melanoma